{"protocolSection": {"identificationModule": {"nctId": "NCT03406078", "orgStudyIdInfo": {"id": "D5180C00009"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma", "officialTitle": "A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SOURCE)", "acronym": "SOURCE"}, "statusModule": {"statusVerifiedDate": "2021-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-03-05", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-09-25", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-09-25", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-01-14", "studyFirstSubmitQcDate": "2018-01-14", "studyFirstPostDateStruct": {"date": "2018-01-23", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-09-22", "resultsFirstSubmitQcDate": "2021-11-10", "resultsFirstPostDateStruct": {"date": "2021-12-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-11-10", "lastUpdatePostDateStruct": {"date": "2021-12-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Amgen", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma", "detailedDescription": "A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Subjects will be randomized in a 1:1 ratio to either tezepelumab or matching placebo both administered subcutaneously", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "maskingDescription": "Double-Blind", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 150, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Tezepelumab", "type": "EXPERIMENTAL", "description": "Tezepelumab subcutaneous injection", "interventionNames": ["Biological: Tezepelumab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo subcutaneous injection", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Tezepelumab", "description": "Tezepelumab subcutaneous injection", "armGroupLabels": ["Tezepelumab"]}, {"type": "OTHER", "name": "Placebo", "description": "Placebo subcutaneous injection", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control", "description": "Categorized percent reduction from baseline at Week 48. Percent change from baseline is defined as {final dose-baseline dose)/baseline dose}\\*100, and the categories of percent change from baseline in daily OCS dose are defined as: \u226590% to \u2264100% reduction, \u226575% to \\<90% reduction, \u226550% to \\<75% reduction, \\>0% to \\<50% reduction, and, no change or any increase.", "timeFrame": "Baseline to Week 48"}], "secondaryOutcomes": [{"measure": "Annualised Asthma Exacerbation Rate (AAER)", "description": "The annualized exacerbation rate is based on exacerbations reported by the investigator in the eCRF over 48 weeks.", "timeFrame": "Baseline to Week 48"}, {"measure": "Proportion of Subjects With 100% Reduction From Baseline in Daily OCS Dose at Week 48", "description": "Proportion (expressed as a percentage) of subjects with 100% reduction from baseline in daily OCS dose at Week 48. Percent change from baseline is defined as {(final dose-baseline dose)/baseline dose}\\*100.", "timeFrame": "Baseline to Week 48"}, {"measure": "Proportion of Subjects With Daily OCS Dose \u22645 mg at Week 48", "description": "Proportion (expressed as a percentage) of subjects with daily OCS dose \u22645 mg at Week 48.", "timeFrame": "Week 48"}, {"measure": "Proportion of Subjects With \u226550% Reduction From Baseline in Daily OCS Dose at Week 48", "description": "Proportion (expressed as a percentage) of subjects with \u226550% reduction from baseline in daily OCS dose at Week 48. Percent change from baseline is defined as {(final dose-baseline dose)/baseline dose}\\*100.", "timeFrame": "Baseline to Week 48"}, {"measure": "Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1)", "description": "Change from baseline in pre-BD FEV1 at Week 48. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.", "timeFrame": "Baseline to Week 48"}, {"measure": "Change From Baseline in Weekly Mean Daily Asthma Symptom Score Via the Daily Asthma Symptom Diary", "description": "Change from baseline in Asthma Symptom Diary score at Week 48. The Asthma Symptom Diary comprises of 10 items (5 items in the morning; 5 items in the evening). Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the daily diary. A daily ASD score is the mean of the 10 items. Responses for all 10 items are required to calculate the daily ASD score; otherwise, it is treated as missing. For the 7-day average asthma symptom score, scoring is done with no imputation using the mean of at least 4 of the 7 daily ASD scores as a mean weekly item score. The 7-day average ASD score ranges from 0 to 4, where 0 indicates no asthma symptoms.", "timeFrame": "Baseline to Week 48"}, {"measure": "Change From Baseline in Weekly Mean Rescue Medication Use", "description": "Change from baseline in weekly mean rescue medication use at Week 48. Daily rescue medication use is defined as: Number of night inhaler puffs + 2 x \\[number of night nebulizer times\\] + number of daytime inhaler puffs + 2 x \\[number of day nebulizer times\\]. Each timepoint is calculated as weekly means based on daily diary data.", "timeFrame": "Baseline to Week 48"}, {"measure": "Change From Baseline in Weekly Mean Home Peak Expiratory Flow (PEF) (Morning and Evening)", "description": "Change from baseline in weekly mean morning and evening peak expiratory flow (PEF) at Week 48. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Each timepoint is calculated as weekly means using at least 4 of the 7 days of PEF data.", "timeFrame": "Baseline to Week 48"}, {"measure": "Change From Baseline in Weekly Mean Number of Night-time Awakening Due to Asthma", "description": "Change from baseline in weekly mean number (expressed as a percentage) of night time awakenings at Week 48. Night-time awakenings percentage defined as number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data and multiplied by 100%. At least 4 out of 7 days of data is required to calculate a weekly mean.", "timeFrame": "Baseline to Week 48"}, {"measure": "Change From Baseline in Asthma Control Questionnaire 6 (ACQ-6) Score", "description": "Change from baseline in ACQ-6 at Week 48. The ACQ-6 captures asthma symptoms and short-acting \u03b22-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.", "timeFrame": "Baseline to Week 48"}, {"measure": "Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s)+12) Total Score", "description": "Change from baseline in AQLQ(S)+12 as compared to placebo at Week 48. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).", "timeFrame": "Baseline to Week 48"}, {"measure": "Change From Baseline in European Quality of Life - 5 Dimensions 5 Levels Questionnaire (EQ-5D-5L) Score", "description": "Change from baseline in EQ-5D-5L at Week 48. The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no/slight/moderate/severe/extreme problems) that reflect increasing levels of difficulty. The EQ-5D-5L scores are converted into a single index-based value (Health State Valuation), using the UK population-based weights. The Helth State Valuation is scored between 0 to 1, where higher score indicates a better health state.", "timeFrame": "Baseline to Week 48"}, {"measure": "Number of Participants With Asthma Specific Resource Utilizations", "description": "Number of participants with asthma specific resource utilizations (e.g. unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications) over 48 weeks.", "timeFrame": "Baseline to Week 48"}, {"measure": "Change From Baseline in Work Productivity and Activity Impairment Questionnaire and Classroom Impairment Questionnaire (WPAI+CIQ) Score", "description": "Change from baseline in WPAI+CIQ score at Week 48. The WPAI+CIQ consists of 10 questions about how asthma and asthma related issues impact a subject's ability to work, attend classes, and perform regular daily activities.\n\nWork (Class) productivity loss is derived by sum of percentage of missed work (class hours) due to asthma and product of percentage of actual working hours (class) times degree of asthma affecting work (class) productivity while working. Percentage of missed work (class hours) due to asthma is calculated by number of hours missed work (class) due to asthma divided by total number of hours missed work (class) plus number of hours actually worked (in class).\n\nActivity impairment is the degree health affected regular activities (other than work or class) rated from 0 to 10, with 0 meaning no effect, divided by 10, and then expressed as a percentage.", "timeFrame": "Baseline to Week 48"}, {"measure": "Change From Baseline in FENO", "description": "Change from baseline in fractional exhaled nitric oxide (FeNO) at week 48.", "timeFrame": "Baseline to Week 48"}, {"measure": "Change From Baseline in Peripheral Blood Eosinophils", "description": "Change from baseline in blood eosinophil counts at week 48.", "timeFrame": "Baseline to Week 48"}, {"measure": "Change From Baseline From Total Serum IgE", "description": "Change from baseline in total serum IgE at week 48.", "timeFrame": "Baseline to Week 48"}, {"measure": "PK: Serum Trough Concentrations", "description": "Serum trough concentrations at each scheduled visit.", "timeFrame": "Pre-dose samples at Baseline, Week 4, Week 12, Week 24, Week 40, Week 48, Week 60"}, {"measure": "Immunogenicity: Incidence of Anti-drug Antibodies (ADA)", "description": "Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \\>=2 post baseline assessments (with \\>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA.", "timeFrame": "Baseline to Week 60"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Subjects must have received a physician-prescribed medium- or high-dose ICS as per GINA guideline for at least 12 months\n2. Subjects must have received physician prescribed LABA and high dose ICS (total daily dose \\>500\u03bcg fluticasone propionate dry powder formulation equivalent) for at least 3 months. The ICS and LABA can be parts of a combination product, or given by separate inhalers.\n3. Additional maintenance asthma controller medications are allowed according to standard practice of care i.e., leukotriene receptor antagonists (LTRAs), theophylline, long-acting muscarinic antagonists (LAMAs), secondary ICS and cromones. The use of these medications must be documented for at least 3 months\n4. Subjects must have received OCS for the treatment of asthma for at least 6 months prior to screening and on a stable dose of between \u2265 7.5 to \u2264 30mg (prednisone or prednisolone equivalent) daily or daily equivalent for at least 1 month. The OCS dose may be administered every other day (or different doses every other day); Average dose over two days = The daily dose.\n5. Morning pre-bronchodilator (BD) FEV1 must be \\< 80% predicted normal\n6. Subjects must have evidence of asthma as documented by post-BD (albuterol/salbutatomol) reversibility of FEV1 \u226512% and \u2265200 mL (15-30 min after administration of 4 puffs of albuterol/salbutamol), documented either in the previous 12 months\n7. Subjects must have a history of at least 1 asthma exacerbation event within 12 months\n8. Minimum 10 days compliance with the morning and evening eDiary completion and OCS,ICS,LABA as well as other asthma controller medications as captured in the eDiary during the 14 days prior to randomization\n9. Documented physician-diagnosed asthma for at least 12 months\n\nExclusion Criteria:\n\n1. Any clinically important pulmonary disease other than asthma (e.g. active lung infection, Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).\n2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:\n\n   Affect the safety of the subject throughout the study Influence the findings of the study or the interpretation Impede the subject's ability to complete the entire duration of study\n3. History of cancer: Subjects who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to visit 1.Subjects who have had other malignancies are eligible provided that curative therapy was completed at least 5 years\n4. A helminth parasitic infection diagnosed within 6 months prior to screening that has not been treated with, or has failed to respond to, standard of care therapy.\n5. Current smokers or subjects with smoking history \u2265 10 pack-years and subjects using vaping products, including electronic cigarettes. Former smokers with a smoking history of \\<10 pack years and users of vaping or e-cigarette products must have stopped for at least 6 months prior to visit 1 to be eligible.\n6. History of chronic alcohol or drug abuse within 12 months\n7. Tuberculosis requiring treatment within the 12 months\n8. History of any known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test.\n9. Major surgery within 8 weeks prior to visit 1 or planned surgical procedures requiring general anaesthesia or in-subject status for \\>1 day during the conduct of the study.\n10. Clinically significant asthma exacerbation, in the opinion of the Investigator, including those requiring use of systemic corticosteroids or increase in the maintenance dose of OCS within 30 days", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Bakersfield", "state": "California", "zip": "93301", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Research Site", "city": "Newark", "state": "Delaware", "zip": "19713", "country": "United States", "geoPoint": {"lat": 39.68372, "lon": -75.74966}}, {"facility": "Research Site", "city": "Kissimmee", "state": "Florida", "zip": "34741", "country": "United States", "geoPoint": {"lat": 28.30468, "lon": -81.41667}}, {"facility": "Research Site", "city": "Kissimmee", "state": "Florida", "zip": "34746", "country": "United States", "geoPoint": {"lat": 28.30468, "lon": -81.41667}}, {"facility": "Research Site", "city": "Fall River", "state": "Massachusetts", "zip": "02721", "country": "United States", "geoPoint": {"lat": 41.70149, "lon": -71.15505}}, {"facility": "Research Site", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "Research Site", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Bronx", "state": "New York", "zip": "10461", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Research Site", "city": "Durham", "state": "North Carolina", "zip": "27705", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Research Site", "city": "Greenville", "state": "North Carolina", "zip": "27834", "country": "United States", "geoPoint": {"lat": 35.61266, "lon": -77.36635}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Cleveland", "state": "Ohio", "zip": "44130", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Research Site", "city": "Toledo", "state": "Ohio", "zip": "43617", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73109", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Altoona", "state": "Pennsylvania", "zip": "16602", "country": "United States", "geoPoint": {"lat": 40.51868, "lon": -78.39474}}, {"facility": "Research Site", "city": "Homestead", "state": "Pennsylvania", "zip": "15120", "country": "United States", "geoPoint": {"lat": 40.4059, "lon": -79.91199}}, {"facility": "Research Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Research Site", "city": "Anderson", "state": "South Carolina", "zip": "29621", "country": "United States", "geoPoint": {"lat": 34.50344, "lon": -82.65013}}, {"facility": "Research Site", "city": "North Charleston", "state": "South Carolina", "zip": "29406", "country": "United States", "geoPoint": {"lat": 32.85462, "lon": -79.97481}}, {"facility": "Research Site", "city": "McKinney", "state": "Texas", "zip": "75069", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78251", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Buenos Aires", "zip": "C1414AIF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Ciudad de Buenos Aire", "zip": "C1425BEN", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "C\u00f3rdoba", "zip": "X5003DCE", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Research Site", "city": "Mendoza", "zip": "5500", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Research Site", "city": "Quilmes", "zip": "B1878FNR", "country": "Argentina", "geoPoint": {"lat": -34.72904, "lon": -58.26374}}, {"facility": "Research Site", "city": "San Fernando", "zip": "1646", "country": "Argentina"}, {"facility": "Research Site", "city": "San Miguel de Tucuman", "zip": "T4000IAR", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Research Site", "city": "Aschaffenburg", "zip": "63739", "country": "Germany", "geoPoint": {"lat": 49.97704, "lon": 9.15214}}, {"facility": "Research Site", "city": "Bamberg", "zip": "96049", "country": "Germany", "geoPoint": {"lat": 49.89873, "lon": 10.90067}}, {"facility": "Research Site", "city": "Berlin", "zip": "10367", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Berlin", "zip": "10717", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Berlin", "zip": "10969", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Hamburg", "zip": "22299", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Research Site", "city": "Hannover", "zip": "30625", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Research Site", "city": "Hannover", "zip": "D-30173", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Research Site", "city": "Koblenz", "zip": "56068", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "Research Site", "city": "L\u00fcbeck", "zip": "23552", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "Research Site", "city": "Mainz Am Rhein", "zip": "55131", "country": "Germany"}, {"facility": "Research Site", "city": "M\u00fcnchen", "zip": "81377", "country": "Germany", "geoPoint": {"lat": 48.13743, "lon": 11.57549}}, {"facility": "Research Site", "city": "Daegu", "zip": "42415", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Research Site", "city": "Seoul", "zip": "03082", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "03312", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "03722", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "05505", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "06351", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "06591", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Krak\u00f3w", "zip": "31-559", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Wroc\u0142aw", "zip": "53-301", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "\u0141\u00f3d\u017a", "zip": "90-153", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Research Site", "city": "Adana", "zip": "01330", "country": "Turkey", "geoPoint": {"lat": 37.00167, "lon": 35.32889}}, {"facility": "Research Site", "city": "Ankara", "zip": "06230", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Research Site", "city": "Ankara", "zip": "06280", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Research Site", "city": "Bursa", "zip": "16059", "country": "Turkey", "geoPoint": {"lat": 40.19559, "lon": 29.06013}}, {"facility": "Research Site", "city": "Istanbul", "zip": "34098", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Research Site", "city": "Manisa", "zip": "45030", "country": "Turkey", "geoPoint": {"lat": 38.61202, "lon": 27.42647}}, {"facility": "Research Site", "city": "Dnipro", "zip": "49007", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Research Site", "city": "Kherson", "zip": "73000", "country": "Ukraine", "geoPoint": {"lat": 46.65581, "lon": 32.6178}}, {"facility": "Research Site", "city": "Lutsk", "zip": "4300", "country": "Ukraine", "geoPoint": {"lat": 50.75932, "lon": 25.34244}}, {"facility": "Research Site", "city": "Vinnytsia", "zip": "21029", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}]}, "referencesModule": {"references": [{"pmid": "35364018", "type": "DERIVED", "citation": "Wechsler ME, Menzies-Gow A, Brightling CE, Kuna P, Korn S, Welte T, Griffiths JM, Salapa K, Hellqvist A, Almqvist G, Lal H, Kaur P, Skarby T, Colice G; SOURCE study group. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022 Jul;10(7):650-660. doi: 10.1016/S2213-2600(21)00537-3. Epub 2022 Mar 29. Erratum In: Lancet Respir Med. 2022 Jul;10(7):e72. doi: 10.1016/S2213-2600(22)00128-X."}, {"pmid": "33050928", "type": "DERIVED", "citation": "Wechsler ME, Colice G, Griffiths JM, Almqvist G, Skarby T, Piechowiak T, Kaur P, Bowen K, Hellqvist A, Mo M, Garcia Gil E. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res. 2020 Oct 13;21(1):264. doi: 10.1186/s12931-020-01503-z."}], "seeAlsoLinks": [{"label": "CSP redacted", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00009&amp;attachmentIdentifier=1c64c2ac-dfb7-45d2-8049-e1f6f24c70ed&amp;fileName=d5180c00009-csp-v4_(14-May-2020).pdf&amp;versionIdentifier="}, {"label": "SAP redacted", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00009&amp;attachmentIdentifier=8bc47970-3cdb-4463-8948-393d1ca86f50&amp;fileName=d5180c00009-sap-ed-3_(22-Oct-2020).pdf&amp;versionIdentifier="}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure\n\nYes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared", "infoTypes": ["STUDY_PROTOCOL", "SAP"], "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure", "accessCriteria": "When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure", "url": "https://astrazenecagroup-dt.pharmacm.com/DT/Home"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The screening period included a Run-in (2 weeks) and an OCS optimization phase (up to 8 weeks). At the end of period, subjects were randomized in 1:1 ratio for tezepelumab or placebo. Randomization was stratified by region (Central/Eastern Europe, Western Europe and North America, Rest of the World).", "recruitmentDetails": "The study was conducted at 60 centres in 7 countries. A total of 243 subjects were screened between 5MAR2018 and 27SEP2019, of which 150 were randomized and treated. 93 subjects were screen failures mainly due to exclusion criteria met and/or inclusion criteria not met. Assignment was done by Interactive Voice/Web Response System(IVRS/IWRS).", "groups": [{"id": "FG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "FG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "74"}, {"groupId": "FG001", "numSubjects": "76"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "68"}, {"groupId": "FG001", "numSubjects": "73"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "BG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "74"}, {"groupId": "BG001", "value": "76"}, {"groupId": "BG002", "value": "150"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.5", "spread": "12.1"}, {"groupId": "BG001", "value": "53.4", "spread": "11.9"}, {"groupId": "BG002", "value": "53.4", "spread": "12.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "94"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "56"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "62"}, {"groupId": "BG001", "value": "64"}, {"groupId": "BG002", "value": "126"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "22"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "24"}]}]}, {"title": "Not Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "64"}, {"groupId": "BG001", "value": "62"}, {"groupId": "BG002", "value": "126"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control", "description": "Categorized percent reduction from baseline at Week 48. Percent change from baseline is defined as {final dose-baseline dose)/baseline dose}\\*100, and the categories of percent change from baseline in daily OCS dose are defined as: \u226590% to \u2264100% reduction, \u226575% to \\<90% reduction, \u226550% to \\<75% reduction, \\>0% to \\<50% reduction, and, no change or any increase.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "76"}]}], "classes": [{"categories": [{"title": ">=90% to <=100% reduction", "measurements": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "35"}]}, {"title": ">=75% to <90% reduction", "measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}]}, {"title": ">=50% to <75% reduction", "measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "14"}]}, {"title": ">0% to <50% reduction", "measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "9"}]}, {"title": "no change or any increase", "measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.434", "statisticalMethod": "Proportional odds model", "statisticalComment": "Response variable: categorised % reduction from baseline in final OCS dose. Covariates in the model: treatment, region and daily OCS dose at baseline.", "paramType": "Cumulative Odds Ratio", "paramValue": "1.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.69", "ciUpperLimit": "2.35"}]}, {"type": "SECONDARY", "title": "Annualised Asthma Exacerbation Rate (AAER)", "description": "The annualized exacerbation rate is based on exacerbations reported by the investigator in the eCRF over 48 weeks.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events per year", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "76"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.38", "lowerLimit": "0.98", "upperLimit": "1.95"}, {"groupId": "OG001", "value": "2.00", "lowerLimit": "1.46", "upperLimit": "2.74"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Subjects With 100% Reduction From Baseline in Daily OCS Dose at Week 48", "description": "Proportion (expressed as a percentage) of subjects with 100% reduction from baseline in daily OCS dose at Week 48. Percent change from baseline is defined as {(final dose-baseline dose)/baseline dose}\\*100.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "76"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "54.1"}, {"groupId": "OG001", "value": "46.1"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Subjects With Daily OCS Dose \u22645 mg at Week 48", "description": "Proportion (expressed as a percentage) of subjects with daily OCS dose \u22645 mg at Week 48.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "76"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "71.6"}, {"groupId": "OG001", "value": "72.4"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Subjects With \u226550% Reduction From Baseline in Daily OCS Dose at Week 48", "description": "Proportion (expressed as a percentage) of subjects with \u226550% reduction from baseline in daily OCS dose at Week 48. Percent change from baseline is defined as {(final dose-baseline dose)/baseline dose}\\*100.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "76"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "74.3"}, {"groupId": "OG001", "value": "69.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1)", "description": "Change from baseline in pre-BD FEV1 at Week 48. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.", "populationDescription": "Number of participants analysed presents the number of subjects with an observation at Week 48. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Litre", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "64"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.21", "spread": "0.046"}, {"groupId": "OG001", "value": "-0.04", "spread": "0.046"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Weekly Mean Daily Asthma Symptom Score Via the Daily Asthma Symptom Diary", "description": "Change from baseline in Asthma Symptom Diary score at Week 48. The Asthma Symptom Diary comprises of 10 items (5 items in the morning; 5 items in the evening). Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the daily diary. A daily ASD score is the mean of the 10 items. Responses for all 10 items are required to calculate the daily ASD score; otherwise, it is treated as missing. For the 7-day average asthma symptom score, scoring is done with no imputation using the mean of at least 4 of the 7 daily ASD scores as a mean weekly item score. The 7-day average ASD score ranges from 0 to 4, where 0 indicates no asthma symptoms.", "populationDescription": "Number of participants analysed presents the number of subjects with an observation at Week 48. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.36", "spread": "0.071"}, {"groupId": "OG001", "value": "-0.26", "spread": "0.068"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Weekly Mean Rescue Medication Use", "description": "Change from baseline in weekly mean rescue medication use at Week 48. Daily rescue medication use is defined as: Number of night inhaler puffs + 2 x \\[number of night nebulizer times\\] + number of daytime inhaler puffs + 2 x \\[number of day nebulizer times\\]. Each timepoint is calculated as weekly means based on daily diary data.", "populationDescription": "Number of participants analysed presents the number of subjects with an observation at Week 48. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Weekly mean rescue medication use", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "70"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.85", "spread": "0.280"}, {"groupId": "OG001", "value": "-0.37", "spread": "0.268"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Weekly Mean Home Peak Expiratory Flow (PEF) (Morning and Evening)", "description": "Change from baseline in weekly mean morning and evening peak expiratory flow (PEF) at Week 48. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Each timepoint is calculated as weekly means using at least 4 of the 7 days of PEF data.", "populationDescription": "Number of participants analysed presents the number of subjects with an observation at Week 48. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "76"}]}], "classes": [{"title": "morning PEF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "70"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.29", "spread": "5.653"}, {"groupId": "OG001", "value": "-9.71", "spread": "5.435"}]}]}, {"title": "evening PEF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "68"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.05", "spread": "5.980"}, {"groupId": "OG001", "value": "-11.37", "spread": "5.749"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Weekly Mean Number of Night-time Awakening Due to Asthma", "description": "Change from baseline in weekly mean number (expressed as a percentage) of night time awakenings at Week 48. Night-time awakenings percentage defined as number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data and multiplied by 100%. At least 4 out of 7 days of data is required to calculate a weekly mean.", "populationDescription": "Number of participants analysed presents the number of subjects with an observation at Week 48. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of nights with awakenings", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "70"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.71", "spread": "3.482"}, {"groupId": "OG001", "value": "-12.79", "spread": "3.317"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire 6 (ACQ-6) Score", "description": "Change from baseline in ACQ-6 at Week 48. The ACQ-6 captures asthma symptoms and short-acting \u03b22-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.", "populationDescription": "Number of participants analysed presents the number of subjects with an observation at Week 48. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.87", "spread": "0.125"}, {"groupId": "OG001", "value": "-0.51", "spread": "0.123"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s)+12) Total Score", "description": "Change from baseline in AQLQ(S)+12 as compared to placebo at Week 48. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).", "populationDescription": "Number of participants analysed presents the number of subjects with an observation at Week 48. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.94", "spread": "0.124"}, {"groupId": "OG001", "value": "0.58", "spread": "0.123"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in European Quality of Life - 5 Dimensions 5 Levels Questionnaire (EQ-5D-5L) Score", "description": "Change from baseline in EQ-5D-5L at Week 48. The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no/slight/moderate/severe/extreme problems) that reflect increasing levels of difficulty. The EQ-5D-5L scores are converted into a single index-based value (Health State Valuation), using the UK population-based weights. The Helth State Valuation is scored between 0 to 1, where higher score indicates a better health state.", "populationDescription": "Number of participants analysed presents the number of subjects with an observation at Week 48. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "spread": "0.026"}, {"groupId": "OG001", "value": "0.00", "spread": "0.027"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Asthma Specific Resource Utilizations", "description": "Number of participants with asthma specific resource utilizations (e.g. unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications) over 48 weeks.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "76"}]}], "classes": [{"title": "Hospitalisation", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "Emergency room visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Unscheduled visit to specialist", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "41"}]}]}, {"title": "Home visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Telephone call", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "43"}]}]}, {"title": "Ambulance transport", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Work Productivity and Activity Impairment Questionnaire and Classroom Impairment Questionnaire (WPAI+CIQ) Score", "description": "Change from baseline in WPAI+CIQ score at Week 48. The WPAI+CIQ consists of 10 questions about how asthma and asthma related issues impact a subject's ability to work, attend classes, and perform regular daily activities.\n\nWork (Class) productivity loss is derived by sum of percentage of missed work (class hours) due to asthma and product of percentage of actual working hours (class) times degree of asthma affecting work (class) productivity while working. Percentage of missed work (class hours) due to asthma is calculated by number of hours missed work (class) due to asthma divided by total number of hours missed work (class) plus number of hours actually worked (in class).\n\nActivity impairment is the degree health affected regular activities (other than work or class) rated from 0 to 10, with 0 meaning no effect, divided by 10, and then expressed as a percentage.", "populationDescription": "The work productivity loss is only applicable to subjects who were employed, which is a subset of the study population. The class productivity loss is only applicable to subjects attending school, which is a subset of the study population. No subject in Placebo arm has selected the option 'in school' on the WPAI+CIQ questionnaire at Week 48.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "76"}]}], "classes": [{"title": "Work productivity loss", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.27", "spread": "25.30"}, {"groupId": "OG001", "value": "-9.66", "spread": "36.63"}]}]}, {"title": "Class productivity loss", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.00", "spread": "0"}]}]}, {"title": "Activity impairment", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.2", "spread": "29.3"}, {"groupId": "OG001", "value": "-7.8", "spread": "26.4"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in FENO", "description": "Change from baseline in fractional exhaled nitric oxide (FeNO) at week 48.", "populationDescription": "Number of participants analysed presents the number of subjects with an observation at Week 48. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ppb", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.71", "spread": "2.757"}, {"groupId": "OG001", "value": "-1.40", "spread": "2.774"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Peripheral Blood Eosinophils", "description": "Change from baseline in blood eosinophil counts at week 48.", "populationDescription": "Number of participants analysed presents the number of subjects with an observation at Week 48. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cells/\u03bcL", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-83.79", "spread": "17.078"}, {"groupId": "OG001", "value": "33.38", "spread": "16.605"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline From Total Serum IgE", "description": "Change from baseline in total serum IgE at week 48.", "populationDescription": "Number of participants analysed presents the number of subjects with an observation at Week 48. All subjects from the Full Analysis Set with at least one change from baseline value at any post baseline visit contributes to the analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "IU/mL", "timeFrame": "Baseline to Week 48", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-80.66", "spread": "36.253"}, {"groupId": "OG001", "value": "37.77", "spread": "35.621"}]}]}]}, {"type": "SECONDARY", "title": "PK: Serum Trough Concentrations", "description": "Serum trough concentrations at each scheduled visit.", "populationDescription": "The placebo arm is not applicable since it is not the experimental product.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "\u03bcg/mL", "timeFrame": "Pre-dose samples at Baseline, Week 4, Week 12, Week 24, Week 40, Week 48, Week 60", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "0"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0", "spread": "0"}]}]}, {"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.3298", "spread": "42.31"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17.9626", "spread": "57.85"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.9210", "spread": "55.83"}]}]}, {"title": "Week 40", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "16.7095", "spread": "181.44"}]}]}, {"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.9224", "spread": "352.35"}]}]}, {"title": "Week 60", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.5591", "spread": "177.36"}]}]}]}, {"type": "SECONDARY", "title": "Immunogenicity: Incidence of Anti-drug Antibodies (ADA)", "description": "Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \\>=2 post baseline assessments (with \\>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 60", "groups": [{"id": "OG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "76"}]}], "classes": [{"title": "ADA positive at baseline and/or post-baseline (ADA prevalence)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Any baseline ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Only baseline ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Any post-baseline ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Both baseline and at least one post-baseline ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Treatment-induced ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Treatment-boosted ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "TE-ADA positive (ADA incidence)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "ADA persistently positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "ADA transiently positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Baseline to Week 60", "eventGroups": [{"id": "EG000", "title": "Tezepelumab", "description": "Tezepelumab 210 mg administered every 4 weeks subcutaneously", "deathsNumAffected": 1, "deathsNumAtRisk": 74, "seriousNumAffected": 12, "seriousNumAtRisk": 74, "otherNumAffected": 35, "otherNumAtRisk": 74}, {"id": "EG001", "title": "Placebo", "description": "Placebo administered every 4 weeks subcutaneously", "deathsNumAffected": 0, "deathsNumAtRisk": 76, "seriousNumAffected": 16, "seriousNumAtRisk": 76, "otherNumAffected": 48, "otherNumAtRisk": 76}], "seriousEvents": [{"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 76}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 76}]}, {"term": "Supraventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 76}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 76}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 76}]}, {"term": "H1n1 influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 76}]}, {"term": "Intervertebral discitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 76}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 76}]}, {"term": "Septic shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 76}]}, {"term": "Incisional hernia", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 76}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 76}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 76}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 76}]}, {"term": "Arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 76}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 76}]}, {"term": "Invasive breast carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 76}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 76}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 76}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 76}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 76}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 11, "numAffected": 8, "numAtRisk": 76}]}, {"term": "Bronchial secretion retention", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 76}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 76}]}], "otherEvents": [{"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 76}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 76}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 76}]}, {"term": "Bronchitis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 6, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 10, "numAffected": 7, "numAtRisk": 76}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 12, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 29, "numAffected": 19, "numAtRisk": 76}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 76}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 76}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 76}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 76}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 76}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 9, "numAffected": 8, "numAtRisk": 76}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 15, "numAffected": 8, "numAtRisk": 76}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 6, "numAffected": 4, "numAtRisk": 76}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 76}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": true}, "pointOfContact": {"title": "Global Clinical Head", "organization": "AstraZeneca", "email": "information.center@astrazeneca.com", "phone": "+1 302 885 1180"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-05-14", "uploadDate": "2021-09-22T04:46", "filename": "Prot_000.pdf", "size": 1886309}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-10-22", "uploadDate": "2021-09-22T04:46", "filename": "SAP_001.pdf", "size": 1371551}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2021-10-20", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}